Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

Despite the introduction of novel agents such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplant, multiple myeloma (MM) largely remains an incurable disease. In recent years, monoclonal antibody-based treatment strategies have been developed to target specific surf...

Full description

Bibliographic Details
Main Authors: Xiang Zhou, Hermann Einsele, Sophia Danhof
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Journal of Clinical Medicine
Subjects:
bispecific antibody
multiple myeloma
relapse
refractory
immunotherapy
Online Access:https://www.mdpi.com/2077-0383/9/7/2166

Similar Items

Similar Items